GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Insight Molecular Diagnostics Inc (NAS:IMDX) » Definitions » E10

IMDX (Insight Molecular Diagnostics) E10 : $-11.25 (As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is Insight Molecular Diagnostics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Insight Molecular Diagnostics's adjusted earnings per share data for the three months ended in Mar. 2025 was $-0.260. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-11.25 for the trailing ten years ended in Mar. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2025-07-14), Insight Molecular Diagnostics's current stock price is $2.86. Insight Molecular Diagnostics's E10 for the quarter that ended in Mar. 2025 was $-11.25. Insight Molecular Diagnostics's Shiller PE Ratio of today is .


Insight Molecular Diagnostics E10 Historical Data

The historical data trend for Insight Molecular Diagnostics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Insight Molecular Diagnostics E10 Chart

Insight Molecular Diagnostics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -11.64

Insight Molecular Diagnostics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -12.23 -12.06 -11.64 -11.25

Competitive Comparison of Insight Molecular Diagnostics's E10

For the Diagnostics & Research subindustry, Insight Molecular Diagnostics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Insight Molecular Diagnostics's Shiller PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Insight Molecular Diagnostics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Insight Molecular Diagnostics's Shiller PE Ratio falls into.


;
;

Insight Molecular Diagnostics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Insight Molecular Diagnostics's adjusted earnings per share data for the three months ended in Mar. 2025 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.26/134.9266*134.9266
=-0.260

Current CPI (Mar. 2025) = 134.9266.

Insight Molecular Diagnostics Quarterly Data

per share eps CPI Adj_EPS
201506 -4.347 100.684 -5.825
201509 -1.903 100.392 -2.558
201512 -2.800 99.792 -3.786
201603 -2.400 100.470 -3.223
201606 -2.000 101.688 -2.654
201609 -2.000 101.861 -2.649
201612 -2.200 101.863 -2.914
201703 -3.200 102.862 -4.198
201706 -2.600 103.349 -3.394
201709 -4.400 104.136 -5.701
201712 -2.600 104.011 -3.373
201803 -2.400 105.290 -3.076
201806 -2.400 106.317 -3.046
201809 -1.400 106.507 -1.774
201812 -2.200 105.998 -2.800
201903 -1.600 107.251 -2.013
201906 -2.071 108.070 -2.586
201909 -2.000 108.329 -2.491
201912 -3.000 108.420 -3.733
202003 -2.600 108.902 -3.221
202006 -2.800 108.767 -3.473
202009 -2.000 109.815 -2.457
202012 -1.800 109.897 -2.210
202103 -1.000 111.754 -1.207
202106 -2.400 114.631 -2.825
202109 -3.000 115.734 -3.497
202112 -7.800 117.630 -8.947
202203 -2.200 121.301 -2.447
202206 -1.480 125.017 -1.597
202209 -1.620 125.227 -1.745
202212 -8.030 125.222 -8.652
202303 0.400 127.348 0.424
202306 -1.070 128.729 -1.122
202309 -0.810 129.860 -0.842
202312 -2.070 129.419 -2.158
202403 -1.130 131.776 -1.157
202406 -0.360 132.554 -0.366
202409 -0.980 133.029 -0.994
202412 -1.930 133.157 -1.956
202503 -0.260 134.927 -0.260

Add all the adjusted EPS together and divide 10 will get our e10.


Insight Molecular Diagnostics  (NAS:IMDX) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Insight Molecular Diagnostics E10 Related Terms

Thank you for viewing the detailed overview of Insight Molecular Diagnostics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Insight Molecular Diagnostics Business Description

Traded in Other Exchanges
Address
15 Cushing, Irvine, CA, USA, 92618
OncoCyte Corp is a pioneering diagnostics technology company. Its mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers, or payers.
Executives
Broadwood Partners Lp 10 percent owner BROADWOOD CAPITAL INC., 142 WEST 57TH STREET, 11TH FLOOR, NEW YORK NY 10019
Andrew Arno director C/O MERRIMAN CURHAN FORD GROUP, INC., 600 CALIFORNIA STREET, 9TH FLOOR, SAN FRANCISCO CA 94108
Josh Riggs officer: Interim CEO 15 CUSHING, IRVINE CA 92618
John Peter Gutfreund other: Former Director 767 5TH AVENUE, 44TH FLOOR, NEW YORK NY 10153
Alfred D Kingsley director 150 E 57TH STREET, NEW YORK NY 10022
Pura Vida Investments, Llc 10 percent owner 512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011
Lou Silverman director
James Yang Liu officer: Controller, PAO C/O ONCOCYTE CORPORATION, 15 CUSHING, IRVINE CA 92618
Andrew J. Last director 3420 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Jennifer L. Carter director C/O DFP SPONSOR LLC, 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Ronald Asbury Andrews director 5791 VAN ALLEN WAY, CARLSBAD CA 92008
Melinda Griffith director 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Anish M. John officer: SVP, Finance, and Interim CFO C/O ONCOCYTE CORPORATION,, 15 CUSHING, IRVINE CA 92618
Li Yu officer: VP Cntrllr/Prncpl Acctng Offcr 120 NEWPORT CENTER DRIVE., NEWPORT BEACH CA 92660
Efrem Kamen 10 percent owner C/O PURA VIDA INVESTMENTS, LLC, 512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011